Anemia in chronic kidney disease. Prevalence and relationship with renal function parameters

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Background. Chronic kidney disease (CKD) is a widespread chronic non-infectious disease that represents a serious medical and social problem. One of the early laboratory manifestations of CKD is anemia, the incidence of which increases as renal dysfunction progresses. Nephrogenic anemia is considered as a factor contributing to the progression of CKD and the development of its complications.

Objective. Assessment of the prevalence of anemia and its relationship with renal function parameters in patients with CKD.

Material and methods. The study included 887 patients with CKD of various etiologies, including 419 men (mean age 47,5 years) and 468 women (mean age 52,4 years). All patients underwent a comprehensive clinical and laboratory examination with an assessment of red blood parameters and renal filtration rates.

Results. Anemia was detected in 50,2% of patients with CKD at the pre- and predialysis stages. Its prevalence among women (51,9%) was slightly higher than among men (48,4%). The average levels of hemoglobin (Hb) and hematocrit (Ht) in men (125,5 g/L and 41,8%, respectively) were significantly higher than in women (111,7 g/L and 38,9%; p<0,05). Hypercholesterolemia was diagnosed more often in women (43,8%) than in men (36,0%). In men with CKD, a significant inverse correlation between the Hb (r=-0,542; p<0,001) and Ht (r=-0,547; p<0,001) concentration with the glomerular filtration rate (GFR), as well as the blood non-protein nitrogen (r=-0,434; p<0,005) and blood urea (r=-0,462; p<0,001) levels was found. In women, the Hb concentration also correlated with the GFR (r=-0.477; p<0.005), blood non-protein nitrogen (r=-0.525; p<0.001) and blood urea level (r=-0,528; p<0,001). In addition, a weak but statistically significant correlation of Hb concentration with total cholesterol level was found in women (r=-0,130; p<0,05), and the red blood cell count correlated with total cholesterol level (r=-0,118; p<0,05).

Conclusion. Anemia occurs in 50.2% of patients with CKD and is an important predictor of chronic renal failure progression, especially in women.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Ilkhom Murkamilov

Kyrgyz State Medical Academy named after I.K. Akhunbaev; Salymbekov University

Хат алмасуға жауапты Автор.
Email: murkamilov.i@mail.ru
ORCID iD: 0000-0001-8513-9279

Dr.Sci. (Med.), Corresponding Member of the Russian Academy of Natural Sciences, Associate Professor at the Department of Faculty Therapy, KSMA n.a. I.K. Akhunbaev, Director of the Multidisciplinary Medical Center «Doc University Clinic», Salymbekov University

Қырғызстан, Bishkek; Bishkek

Kubanych Aitbaev

Kyrgyz Research Institute of Animal Husbandry and Pastures

Email: aitbaev.kuban1940@gmail.com
ORCID iD: 0000-0003-4973-039X

Dr.Sci. (Med.), Professor, Head of the Department of Pathological Physiology, Research Institute of Molecular Biology and Medicine

Қырғызстан, Bishkek

Viktor Fomin

Sechenov First Moscow State Medical University

Email: fomin_vic@mail.ru
ORCID iD: 0000-0002-2682-4417

Dr.Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences, Head of the Department of Faculty Therapy No. 1, N.V. Sklifosovsky Institute of Clinical Medicine, Vice-Rector for Innovation and Clinical Activities

Ресей, Moscow

Zafarbek Raimzhanov

Burdenko Main Military Clinical Hospital

Email: rzrmam@mail.ru
ORCID iD: 0000-0001-5746-6731

Neurologist, 29th Neurological Department

Ресей, Moscow

Shavkat Khakimov

Salymbekov University

Email: hakimovshaki13@gmail.com
ORCID iD: 0009-0004-0437-0188

Head of the Department of Critical Care, Therapy and Diagnostics

Қырғызстан, Bishkek

Gulzat Duysheeva

Kyrgyz State Medical Academy named after I.K. Akhunbaev

Email: guzyu_88@mail.ru
ORCID iD: 0000-0002-8847-5937

Teaching Assistant at the Department of Faculty Therapy

Қырғызстан, Bishkek

Islombek Abdurakhmanov

Saint Petersburg State University

Email: ali_islam95@mail.ru
ORCID iD: 0009-0006-0660-0113

Therapist, Researcher, City Polyclinic №120

Ресей, Saint Petersburg

Zhaloliddin Solizhonov

Kazan State Medical University

Email: jaloliddinsolijonov44@gmail.com
ORCID iD: 0009-0003-0078-0609

6th-year student at the Faculty of General Medicine

Ресей, Kazan

Yodgor Boymurodov

Kazan State Medical University

Email: yodiboymurodov@gmail.com
ORCID iD: 0009-0000-5966-1450

4th year student at the Faculty of General Medicine

Ресей, Kazan

Tursunoy Yusupova

Osh State University

Email: yusupova_tursunoy_f@mail.ru
ORCID iD: 0000-0002-8502-2203

Clinical Resident at the Department of Neurology, Neurosurgery and Psychiatry, Medical Faculty

Қырғызстан, Osh

Zulhumor Yusupova

Osh State University

Email: zulkhumor.yusupova.f_05@mail.ru
ORCID iD: 0000-0001-7621-1128

4th year student at the Medical Faculty

Қырғызстан, Osh

Furkat Yusupov

Osh State University

Email: furcat_y@mail.ru
ORCID iD: 0000-0003-0632-6653

Dr.Sci. (Med.), Professor, Head of the Department of Neurology, N eurosurgery and Psychiatry, Faculty of Medicine

Қырғызстан, Osh

Ibadilla Abdibaliev

Loginov Moscow Clinical Scientific and Practical Center

Email: murkamilov.i@mail.ru

Researcher

Ресей, Moscow

Kamranbey Gasanov

Kyrgyz State Medical Academy named after I.K. Akhunbaev

Email: gassanov_k@mail.ru
ORCID iD: 0000-0003-0173-8851

Researcher

Қырғызстан, Bishkek

Komil Khabibullaev

Kyrgyz State Medical Academy named after I.K. Akhunbaev

Email: khabibullaevkomil2001@gmail.com
ORCID iD: 0009-0004-5508-8019

6th year student at the Faculty of Medicine

Қырғызстан, Bishkek

Daniyar Ymankulov

Green Clinic Medical Center

Email: ymankulov9595@mail.ru
ORCID iD: 0009-0000-4975-1196

Researcher, Plastic Surgeon

Қырғызстан, Bishkek

Әдебиет тізімі

  1. Шилов Е.М., Шилова М.М., Румянцева Е.И. и др. Нефрологическая служба Российской Федерации 2023: часть II. Ресурсы и кадры. Клин. нефрология. 2024;4:5–11. [Shilov E.M., Shilova M.M., Rumyantseva E.I., et al. Nephrology service of the Russian Federation 2023: Part II. Resources and staff. Clin. Nephrol. 2024;4:5–11 (In Russ.)]. doi: 10.18565/nephrology.2024.4.5-11.
  2. Romagnani P., Agarwal R., Chan J.C.N., et al. Chronic kidney disease. Nat. Rev. Dis. Primers. 2025;11(1):8. doi: 10.1038/s41572-024-00589-9.
  3. Park Y., Hwang W.M. Management of Elderly Patients with Chronic Kidney Disease. Yonsei Med. J. 2025;66(2):63–74. doi: 10.3349/ymj.2024.0178.
  4. Matsushita K., Ballew S.H., Wang A.Y., et al. Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease. Nat. Rev. Nephrol. 2022;18(11):696–707. doi: 10.1038/s41581-022-00616-6.
  5. Retat L., Xiao D., Webber L., et al. Correction to: Inside ANEMIA of CKD: Projecting the Future Burden of Anemia of Chronic Kidney Disease and Benefits of Proactive Management: A Microsimulation Model of the Chinese Population. Adv. Ther. 2025;42(1):556–8. doi: 10.1007/s12325-024-03012-7. [Epub 2024 Nov 14]. Erratum for: Adv. Ther. 2024;41(10):3905–21. doi: 10.1007/s12325-024-02863-4.
  6. Милованов Ю.С., Козловская Л.В., Милованова Л.Ю. и др. Факторы риска развития анемии на ранних стадиях хронической болезни почек. Тер. архив. 2017;89(6):41-7. [Milovanov Iu.S., Kozlovskaia L.V., Milovanova L.Iu., et al. Risk factors for anemia in the early stages of chronic kidney disease. Ther. Arch. 2017;89(6):41-7 (In Russ.)]. doi: 10.17116/terarkh201789641-47.
  7. Милованов Ю.С., Милованова Л.Ю., Козловская Л.В. Нефрогенная анемия: патогенез, прогностическое значение, принципы лечения. Клин. нефрология. 2010;6:7–18. [Milovanov J.S., Milovanova L.J., Kozlovskaya L.V. Anaemia in chronic kidney disease: pathogenesis, prognostic sighnificance, treatment. Clin. Nephrol. 2010;6:7–18 (In Russ.)].
  8. Lu Z., Lu F., Zhang R., Guo S. Interaction between anemia and hyperuricemia in the risk of all-cause mortality in patients with chronic kidney disease. Front. Endocrinol. (Lausanne). 2024;15:1286206. doi: 10.3389/fendo.2024.1286206
  9. Клинические рекомендации. Хроническая болезнь почек (ХБП). Нефрология. 2021;25(5):10–82. [Clinical recommendations. Chronic kidney disease (CKD). Nephrology. 2021;25(5):10–82 (In Russ.)]. doi: 10.36485/1561-6274-2021-25-5-10-82.
  10. Шестакова М.В. Сахарный диабет и хроническая болезнь почек: возможности прогнозирования, ранней диагностики и нефропротекции в XXI веке. Тер. архив. 2016;88(6):84-8. [Shestakova M.V. Diabetes mellitus and chronic kidney disease: Possibilities of prediction, early diagnosis, and nephroprotection in the 21st century. Ther. Arch. 2016;88(6):84-8 (In Russ.)]. doi: 10.17116/terarkh201688684-88.
  11. Анциферов М.Б., Демидов Н.А. Эффективность дапаглифлозина в отношении улучшения клинических исходов у пациентов с сахарным диабетом 2-го типа (продолжение исследования CARDIA-MOS, Москва). Сахарный диабет. 2025;28(1):80–90. [Antsiferov M.B., Demidov N.A. Dapagliflozin effectiveness in improvement of clinical outcomes in diabetic patients (extention of CARDIA-MOS study, Moscow). Diab. Mellit. 2025;28(1):80–90 (In Russ.)]. doi: 10.14341/DM13262.
  12. Мартынов С.А., Шестакова М.В., Шилов Е.М. и др. Распространенность анемии у больных сахарным диабетом 1-го и 2-го типа с поражением почек. Сахарный диабет. 2017;20(5):318–28. [Martynov S.A., Shestakova M.V., Shilov E.M., et al. Prevalence of anemia in patients with type 1 and type 2 diabetes mellitus with chronic renal disease. Diab. Mellit. 2017;20(5):318–28 (In Russ.)]. doi: 10.14341/DM9369.
  13. Добронравов В.А., Смирнов А.В. Анемия и хроническая болезнь почек. Анемия.2005;2:2–8. [Dobronravov VA., Smirnov A.V. Anemia and chronic kidney disease. Anemia. 2005;(2):2–8 (In Russ.)].
  14. Добронравов В.А., Смирнов А.В., Безруких А.М. и др. Анемия и преддиализные стадии хронической болезни почек: клиническое значение, распространенность и факторы риска. Нефрология. 2006;10(3):7–13. [Dobronravov V.A., Smirnov A.V., Bezrukikh A.M., et al. Anemia and pre-dialysis stages of chronic kidney disease: clinical significance, incidence and risk factors. Nephrology. 2006;10(3):7–13 (In Russ.)]. Doi: 10.24884/ 1561-6274-2006-10-3-7-13.
  15. Кобалава Ж.Д., Виллевальде С.В., Багманова Н.Х. и др. Распространенность маркеров хронической болезни почек у пациентов с артериальной гипертонией в зависимости от наличия сахарного диабета: результаты эпидемиологического исследования хронограф. Рос. кардиол. журн. 2018;(2):91–101. [Kobalava Zh.D., Villevalde S.V., Bagmanova N.Kh., et al. The prevalence of chronic kidney disease markers in arterial hypertension patients and relation with diabetes: results of epidemiological study khronograph. Rus. J. Cardiol. 2018;(2):91–101 (In Russ.)]. doi: 10.15829/1560-4071-2018-2-91-101.
  16. Муркамилов И.Т., Айтбаев К.А., Фомин В.В. Распространенность, возрастные и гендерные особенности хронической болезни почек у больных сахарным диабетом. Тер. архив. 2023;95(6):481–6. [Murkamilov I.T., Aitbaev K.A., Fomin V.V. Prevalence, age and gender features of chronic kidney disease in patients with diabetes mellitus. Ter. Arkh. 2023;95(6):481–6 (In Russ.)]. doi: 10.26442/00403660.2023.06.202242.
  17. Чеботарева Н.В., Советников Е.Н., Бернс А.С. и др. Нарушения гемостаза, оцененные с помощью глобальных тестов, у больных хроническим гломерулонефритом с нефротическим синдромом. Профилактическая медицина. 2022;25(12):119-26. [Chebotareva N.V., Sovetnikov E.N., Berns A.S., et al. Hemostasis disorders assessed by global tests in patients with chronic glomerulonephritis and nephrotic syndrome. Rus. J. Prevent. Med. 2022;25(12):119-26 (In Russ.)]. https://doi.org/10.17116/profmed202225121119.
  18. Стемпень Т.П., Лелевич С.В. Клиническая лабораторная гематология: пособие для студентов медико-диагностического факультета (специальность 1-79 01 04 «Медико-диагностическое дело») с приложением на компакт-диске. Гродно, 2016. 232 с. [Stempen T.P., Lelevich S.V. Clinical laboratory hematology: a manual for students of the Faculty of Medicine and Diagnostics (specialty 1-79 01 04 “Medical diagnostic business”) with a CD-ROM attachment. Grodno, 2016. 232 p. (In Russ.)].
  19. Macdougall I.C. Anaemia in CKD-treatment standard. Nephrol. Dial. Transplant. 2024;39(5):770–7. doi: 10.1093/ndt/gfad250.
  20. Kawai K., Ishii M., Kokado Y., et al. Outcomes of Early Versus Delayed Anemia Treatment in Nondialysis-Dependent CKD. Kidney Int. Rep. 2024;9(7): 2056–66. doi: 10.1016/j.ekir.2024.04.030.
  21. Tian L., Wang M., Liu M., et al. Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysis. Ren. Fail. 2024;46(1):2313864. doi: 10.1080/0886022X.2024.2313864.
  22. Рябова Т.С., Ракитянская И.А. Анемия при хронической болезни почек. Вестн. терапевта. 2021;4(51). [Riabova T.S., Rakityanskaya I.A. Anemia in chronic kidney disease. Therapist’s Bulletin. 2021;4(51) (In Russ.)]. URL: https://therapyedu.su/statyi/anemija-pri-hronicheskoj-bolezni-pochek.
  23. Лыков А.П. Эритропоэтин: функции и терапевтический потенциал. Сибирский научный медицинский журнал. 2023;43(3):29–39. [Lykov A.P. Erythropoietin: function and therapeutic potential. Siber. Sci. Med. J. 2023;43(3):29–39 (In Russ.)]. doi: 10.18699/SSMJ20230203.
  24. Милованов Ю.С., Козловская Л.В., Николаев А.Ю. и др. Анемия у больных с хронической почечной недостаточностью. Леч. врач.2005;7:16–21. [Milovanov Yu.S., Kozlovskaya L.V., Nikolaev A.Yu., et al. Anemia in patients with chronic renal failure. Lech. Vrach. 2005;7:16–21 (In Russ.)].
  25. Шило В.Ю., Земченков А.Ю., Гуревич К.Я. и др. Российские национальные рекомендации по диагностике и лечению анемии при хронической болезни почек. Нефрология и диализ. 2016;18(1):19–34. [Shilo V.Yu., Zemchenkov A.Yu., Gurevich K.Ya., et al. Russian national clinical recommendations for diagnosis and treatment of anemia in chronic kidney disease. Nephrol. Dial. 2016;18(1):19–34 (In Russ.)].
  26. Roth D., Smith R., Schulman G., et al. Effect of rhEPO on renal funtion in predislysis patients. Am. J. Kidney Dis.1994;24:777–84.
  27. Hue J.L., St Peter W.R., Ebben J.P., et al. Anemia treatment in the pre-ESRD period and associated mortality in elderly patients. Am. J. Kidney Dis. 2002;40:1153–61.
  28. Марков А.А., Костиков А.П., Поснов А.А. Анемия при хроническом заболевании почек и ее влияние на развитие заболевания. Уральский медицинский журнал. 2020;10(193):12–6. [Markov A.A., Kostikov A.P., Postnov А.А. Anemia in chronic kidney disease and its impact on the development of the disease. Ural. Med. J. 2020;10(193):12–6 (In Russ.)]. doi: 10.25694/URMJ.2020.10.08.
  29. Котенко О.Н., Абольян Л.В., Кутейников В.Ю. и др. Анемия и качество жизни пациентов с хронической болезнью почек на заместительной почечной терапии методом программного гемодиализа. Тер. архив. 2023;95(1):32–7. [Kotenko O.N., Abolyan L.V., Kuteinikov V.Iu., et al. Anemia and quality of life of chronic kidney disease patients on renal replacement therapy by programmed hemodialysis. Ter. Arkh. 2023;95(1): 32–7 (In Russ.)]. doi: 10.26442/00403660.2023.01.202050.
  30. Шутов Е.В. Спорные вопросы лечения анемии у больных с ХБП. Новые возможности. Эффективная фармакотерапия. 2023;19 (2):6–11. [Shutov E.V. Controversial Issues of Anemia Treatment in Patients with CKD. New Possibilities. Effect. Pharmacother. 2023;19 (2):6–11 (In Russ.)]. doi: 10.33978/2307-3586-2023-19-2-6-11.
  31. Sarnak M.J., Jaber B.L. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int. 2000;58(4):1758–64.
  32. Litton E., Xiao J., Ho K.M. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials. BMJ. 2013;347:f4822.
  33. Saran R., Robinson B., Abbott K.C. US renal data system 2018 annual data report: epidemiology of kidney disease in the United States. Am. J. Kidney Dis. 2019;73(3 Suppl. 1) :A7–8.
  34. Khan M.S., Spertus J.A., Chan P.S. Transfusion Strategy in Myocardial Infarction and Anemia. N. Engl. J. Med. 2024;390(10):960–1. doi: 10.1056/NEJMc2400982.
  35. Бондаренко Н.Б., Батюшин М.М., Гасанов М.З. и др. Патогенетические особенности системной гипоксии у пациентов с хронической болезнью почек 5Д стадии, получающих лечение гемодиализом. Клин. нефрология. 2019;1:42–7. [Bondarenko N.B., Batyushin M.M., Gasanov M.Z., et al. Pathogenetic features of systemic hypoxia in patients with chronic kidney disease stage 5d-on hemodialysis. Clin. Nephrol. 2019;1:42–7 (In Russ.)]. doi: 10.18565/nephrology.2019.1.42-47.
  36. Ткаченко Е.И., Боровкова Н.Ю., Буянова М.В. Анемия при хронической сердечной недостаточности: взгляд на патогенез и пути коррекции. Доктор. Ру. 2019;2(157):31–6. [Tkachenko E.I., Borovkova N.Yu., Buyanova M.V., et al. Anemia in Patients with Chronic Heart Failure: A View of Pathogenesis and Treatment Options. Doctor. Ru. 2019;2(157):31–6 (In Russ.)]. doi: 10.31550/1727-2378-2019-157-2-31-36.
  37. Смирнова Д.В., Барышева О.Ю., Тихова Г.П. Анализ эффективности коррекции анемии при хронической болезни почек 5 стадии по данным ГБУЗ РК «Республиканская больница им. В.А. Баранова». Нефрология. 2024;28(4):82–90. [Smirnova D.V., Barysheva O.Yu., Tikhova G.P. Analysis of the effectiveness of anemia correction in CKD stage 5 on the basis of the “V.A. Baranov Republican Hospital” in Karelia Republic. Nephrology. 2024;28(4):82–90 (In Russ.)]. doi: 10.36485/1561-6274-2024-28-4-82-90.
  38. Liang X.L., Huang R.W., Xie J.T., et al. Enarodustat for the Treatment of Anemia in Chinese Patients with Non-Dialysis Chronic Kidney Disease: A Phase 3 Trial. Kidney Dis (Basel). 2024;11(1):49–62. Doi: 10.1159/ 000543193.
  39. Kim D., Lee J., Toyama T., et al. Asian Renal Collaboration. Prevalence and Treatment Patterns of Anaemia in Individuals With Chronic Kidney Disease Across Asia: A Systematic Review and Meta-Analysis. Nephrology (Carlton). 2025;30(2):e70002. doi: 10.1111/nep.70002.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу
2. Fig. 1. Relationship between НЬ level and GFR in а group of men with CKD

Жүктеу (227KB)
Метадеректер
3. Fig. 2. Relationship between Ht level and GFR in а group of men with CKD

Жүктеу (250KB)
Метадеректер
4. Fig.3. Relationship between НЬ level and GFR in а group of women with CKD

Жүктеу (218KB)
Метадеректер
5. Fig. 4. Relationship between Ht level and GFR in а group of women with CKD

Жүктеу (253KB)
Метадеректер
6. Fig. 5. Relationship between НЬ level and Ыооd urea level in а group of men with CKD

Жүктеу (193KB)
Метадеректер
7. Fig. 6. Relationship between НЬ level and blооd urea level in а group of women with CKD

Жүктеу (198KB)
Метадеректер
8. Fig. 7. Relationship between НЬ level and blood non-protein nitrogen level in а group of men with CKD

Жүктеу (215KB)
Метадеректер
9. Fig. 8. Relationship between НЬ concentration and blood non-protein nitrogen level in а group of women with CKD

Жүктеу (242KB)
Метадеректер
10. Fig. 9. Relationship between НЬ level and blood ТС level in а group of women with CKD

Жүктеу (216KB)
Метадеректер
11. Fig. 10. The relationship between red blood cell count and the blood ТС level in а group of women with CK

Жүктеу (240KB)
Метадеректер